When Selectivity Increases Uncertainty: Context‐Dependent Pharmacology in Antibody Drug Development

As antibody therapeutics become increasingly selective and multi-specific, their pharmacological effects depend more strongly on biological context, creating new uncertainties in drug development. In this perspective, we discuss how context-dependent pharmacology complicates preclinical-to-clinical translation, dose optimization, and rational combination therapy selection for antibody drugs. Recognizing context dependence is essential for realizing the full therapeutic potential of highly selective biologics and for advancing a more predictive, mechanism-informed paradigm in antibody drug development.